Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

Gene Therapy volume 6, pages 350–363 (1999)Cite this article

Abstract

We conducted a phase 1 trial of direct injection of an E1,E3-deleted adenovirus encoding interleukin-2 (AdCAIL-2) into subcutaneous deposits of melanoma or breast cancer. Twenty-three patients were injected at seven dose levels (107–1010 p.f.u). Local inflammation was observed at the site of injection in 60% of patients, but side-effects were otherwise minor. Incomplete local tumor regression occurred at the site of injection in 24% of patients, but no conventional clinical responses were seen. Circulating CD4 and CD8 counts fell significantly 24 h after injection. Post-injection biopsies demonstrated tumor necrosis and lymphocytic infiltration with the predominant tumor-infiltrating cells both CD3- and CD8-positive. Vector-derived sequences were detected in 14 of 18 biopsies examined 7 days after injection and vector-derived hIL-2 mRNA was detected in 80% of 7-day biopsies processed after injection of 108 p.f.u. of AdCAIL-2 or higher. While IL-2 was detectable by ELISA in tumor biopsies at 48 h, no protein was detectable in injected tumors after 7 days and no circulating IL-2 was detectable at any time-point. No Ad5E1 sequences were detected either before or after injection indicating absence of replication-competent virus or endogenous E1-like sequence; furthermore, only rare vector shedding was detected. Anti-adenovirus and neutralizing antibody titers were elevated 1 month after injection in all patients. This trial therefore confirms the safety of use of adenoviral vectors for gene delivery in humans and demonstrates successful transgene expression even in the face of pre-existing immunity to adenovirus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12

Similar content being viewed by others

References

  1. Rosenberg SA et al. Human gene marker/therapy clinical protocols Hum Gene Ther 1997 8: 2301–2338

    Article  CAS  PubMed  Google Scholar 

  2. Zhai Y et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy J Immunol 1996 156: 700–710

    CAS  PubMed  Google Scholar 

  3. Stewart AK et al. A phase I study of adenovirus-mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma Hum Gene Ther 1997 8: 1403–1414

    Article  CAS  PubMed  Google Scholar 

  4. Toloza EM et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector Cancer Gene Ther 1996 3: 11–17

    CAS  PubMed  Google Scholar 

  5. Sewell DA et al. Safety of in vivo adenovirus-mediated thymidine kinase treatment of oral cancer Arch Otolaryngol Head Neck Surg 1997 123: 1298–1302

    Article  CAS  PubMed  Google Scholar 

  6. Santoso JT et al. Adenovirus-based p53 gene therapy in ovarian cancer (see comments) Gynecol Oncol 1995 59: 171–178

    Article  CAS  PubMed  Google Scholar 

  7. Gahery-Segard H et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products J Clin Invest 1997 100: 2218–2226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Esandi MC et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene Gene Therapy 1997 4: 280–287

    Article  CAS  PubMed  Google Scholar 

  9. Graham FL, Prevec L . Adenovirus expression vectors and recombinant vaccines. In: Ellis RW (ed) . Vaccines: New Approaches to Immunological Problems Butterworth-Heinemann: Boston 1992 364–390

    Google Scholar 

  10. Gahery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity J Virol 1998 72: 2388–2397

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Clayman GL et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma J Clin Oncol 1998 16: 2221–2232

    Article  CAS  PubMed  Google Scholar 

  12. Rosenberg SA . Keynote address: perspectives on the use of interleukin-2 in cancer treatment Cancer J Sci Am 1997 3 (Suppl. 1): S2–S6

    Google Scholar 

  13. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 1990 60: 397–403

    Article  CAS  PubMed  Google Scholar 

  14. Gansbacher B, Rosenthal FM, Zier K . Retroviral vector-mediated cytokine-gene transfer into tumor cells Cancer Invest 1993 11: 345–354

    Article  CAS  PubMed  Google Scholar 

  15. Porgador A et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells Int J Cancer 1993 53: 471–477

    Article  CAS  PubMed  Google Scholar 

  16. Zier KS, Salvadori S, Cronin KC, Gansbacher B . Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness Cancer Gene Ther 1994 1: 43–50

    CAS  PubMed  Google Scholar 

  17. Rosenthal FM et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs Blood 1994 83: 1289–1298

    CAS  PubMed  Google Scholar 

  18. Alosco T et al. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells Cancer Immunol Immunother 1993 36: 364–372

    Article  CAS  PubMed  Google Scholar 

  19. Tsai SC et al. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts J Natl Cancer Inst 1993 85: 546–553

    Article  CAS  PubMed  Google Scholar 

  20. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E . The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity J Immunol 1994 152: 2324–2332

    CAS  PubMed  Google Scholar 

  21. Lindauer M et al. Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells J Mol Med 1996 74: 43–49

    Article  CAS  PubMed  Google Scholar 

  22. Iwanuma Y, Kato K, Yagita H, Okumura K . Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene Cancer Immunol Immunother 1995 40: 17–23

    Article  CAS  PubMed  Google Scholar 

  23. Haddada H et al. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces anti-tumoral immunity in mice Hum Gene Ther 1993 6: 703–711

    Article  Google Scholar 

  24. Addison CL et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model Proc Natl Acad Sci USA 1995 92: 8522–8526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Addison CL et al. Intratumoral co-injection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Therapy 1998 5: 1400–1409

    Article  CAS  PubMed  Google Scholar 

  26. Mittereder N et al. Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA Hum Gene Ther 1994 5: 717–729

    Article  CAS  PubMed  Google Scholar 

  27. Rosenecker J et al. Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer Infection 1996 24: 5–8

    Article  CAS  PubMed  Google Scholar 

  28. Zabner J et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis J Clin Invest 1996 97: 1504–1511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yang Y, Greenough K, Wilson JM . Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver Gene Therapy 1996 3: 412–420

    CAS  PubMed  Google Scholar 

  30. Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination Gene Therapy 1997 4: 1069–1076

    Article  CAS  PubMed  Google Scholar 

  31. Tursz T et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients J Natl Cancer Inst 1996 88: 1857–1863

    Article  CAS  PubMed  Google Scholar 

  32. Marr RA et al. Tumour immunotherapy using an adenoviral vector expressing a membrane- bound mutant of murine TNF alpha Gene Therapy 1997 4: 1181–1188

    Article  CAS  PubMed  Google Scholar 

  33. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum Gene Ther 1996 7: 1995–2002

    Article  CAS  PubMed  Google Scholar 

  34. Putzer BM et al. Interleukin-12 and B7–1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression Proc Natl Acad Sci USA 1997 94: 10889–10894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Toronto Hospital/Princess Margaret Hospital, Ontario, Canada

    A K Stewart, I C Quirt, D J Bailey, L E Rotstein, M Krajden & D Cappe

  2. Sunnybrook Regional Cancer Center, Ontario, Canada

    N J Lassam

  3. Mount Sinai Hospital, University of Toronto, Ontario, Canada

    S Dessureault & S Gallinger

  4. McMaster University, Hamilton, Ontario, Canada

    Y Wan, C L Addison, J Gauldie & F L Graham

  5. Baxter Health Care Gene Therapy Division, Round Lake, IL, USA

    R C Moen

Authors
  1. A K Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N J Lassam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I C Quirt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D J Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L E Rotstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Krajden
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Dessureault
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Gallinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Cappe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C L Addison
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R C Moen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Gauldie
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F L Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, A., Lassam, N., Quirt, I. et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6, 350–363 (1999). https://doi.org/10.1038/sj.gt.3300833

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300833

Keywords

This article is cited by

Search

Advanced search

Quick links